Search Within

Weinberg Fellows

Formats
  1. Meeting Abstract (1379)
  2. Journal Article (1159)
  3. Review (130)
  4. Editorial (65)
  5. Research Letter (36)
  6. Correspondence (26)
  7. Book Section (25)
  8. Guidelines (12)
  9. Conference Paper (2)
  10. Miscellaneous (2)
Groups
  1. Hematology-Oncology Fellows (2763)
  2. Department of Medicine (2720)
  3. Solid Tumor Oncology Division (2017)
  4. Hematologic Malignancies, Division of (1337)
  5. GSK Faculty (1233)
  6. Department of Pathology and Laboratory Medicine (988)

More Groups

People
  1. Michael Berger (220)
  2. Marc Ladanyi (198)
  3. Pedram Razavi (184)
  4. Michael Offin (177)
  5. Sergio Giralt (171)
  6. David Solit (169)

More People

Years
  1. 2025 (223)
  2. 2024 (414)
  3. 2023 (330)
  4. 2022 (377)
  5. 2021 (339)
  6. 2020 (323)

More Years

Publications
  1. Journal of Clinical Oncology (568)
  2. Blood (299)
  3. Annals of Oncology (107)
  4. Clinical Cancer Research (102)
  5. Journal of Thoracic Oncology (96)
  6. Cancer Research (87)

More Publications

Publishers
  1. American Society of Clinical Oncology (645)
  2. Elsevier Inc. (344)
  3. American Society of Hematology (339)
  4. American Association for Cancer Research (241)
  5. Nature Publishing Group (202)
  6. Oxford University Press (157)

More Publishers

Results (2836)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Iyengar, V.; Chicola, J.; Joseph, A.; Okwali, M.; Truong, R.; Bapodra, N.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CD371-targeted CAR T-cells secreting interleukin-18 exhibit robust expansion and disease clearance in patients with refractory acute myeloid leukemia
    Meeting Abstract

    Geyer, M. B.; Dewolf, S.; Mi, X.; Shaffer, B. C.; Cadzin, B.; McAvoy, D.; Hosszu, K. K.; Weis, K.; Lorenc, R.; Lewis, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Brown, S.; Devlin, S. M.; Costa, B. A.; Farzana, T.; Jurgens, E. M.; Firestone, R. S.; Nath, K.; Chung, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Prognostic impact of measurable residual disease evaluated by next generation flow and PET-CT in clinical practice at Fundación Santa Fe de Bogotá Hospital, Colombia
    Meeting Abstract

    Romero Prieto, M.; Melo Arias, A.; Oros, J. G.; Ovalle, N. T.; Ucros, G.; Galvis, K.; Martinez, D.; Cuellar, G.; Saavedra, C.; Martin, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Devimistat results in a low complete remission rate in heavily pre-treated Burkitt lymphoma
    Meeting Abstract

    Steiner, R.; Nikolaenko, L.; Kambhampati, S.; Khan, N.; Nair, R.; Abramson, J. S.; Horwitz, S.; Matasar, M.; Owens, C.; Rodriguez Rivera, I. I.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K. L.; Slupe, N.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • High grade B-cell lymphoma with MYC/BCL6-rearrangements (R) may have inferior outcomes compared to BCL2-R disease
    Meeting Abstract

    Healton, S. E.; Luttwak, E.; Rivas-Delgado, A.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Venetoclax-based therapy versus intensive chemotherapy followed by allogeneic-stem cell transplantation for high-risk elderly acute myeloid leukemia
    Meeting Abstract

    Iat, A.; Bewersdorf, J. P.; Gilhodes, J.; Liu, Y.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Bystrom, R. P.; Deangelo, D. J.; Berton, G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Adult AML patients with NUP98 fusions are frequently therapy-related, and are associated with monocytic differentiation, recurring mutations in NRAS, DNMT3A and WTI and poor outcome
    Meeting Abstract

    Yao, J.; Aypar, U.; Sethi, S.; Boussi, L.; Londono, D.; Sukhadia, P.; Berman, E.; Stein, E. M.; Dogan, A.; Xiao, W.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
    Blood (2024)

    Fulltext@MSK | Save